Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Completed · Phase 2

Conditions studied: Glaucoma, Ocular Hypertension

In brief

This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient

Key facts

Study ID

NCT00652496

Run by

Allergan

People needed

249

Starts

2005-01-01

Expected to finish

2005-05-01

Last updated by the study team

2008-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ocular hypertension or glaucoma in both eyes
• Require IOP-lowering therapy in each eye

You may not qualify if…

• Uncontrolled systemic disease
• Known allergy or hypersensitivity to bimatoprost

Where it is running

• Study site — Wenatchee, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.